Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03526887
Title Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)
Acronym Replay
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Spanish Lung Cancer Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP

Additional content available in CKB BOOST